Immunotherapy Boosts Lung Cancer Survival

Long-term data show that PD-1 checkpoint inhibitors improve survival for people with advanced non-small-cell lung cancer (NSCLC), including those with the lowest PD-L1 levels. Martin Reck, MD, PhD, of Lung Clinic Grosshansdorf in Germany, presented updated results from a Phase III trial comparing Keytruda (pembrolizumab) versus chemotherapy as a first treatment for people with advanced NSCLC with high PD-L1 levels (50% or greater).
Read more...

;